Clinical study of factors associated with pregnancy outcomes in pregnant women with systemic lupus erythematosus in the southern China

Abstract

Objectives: This study aims to estimate predicted factors for maternal and fetal outcomes in Hakka pregnant women with systemic lupus erythematosus (SLE) in the southern China.

Patients and methods: Between June 2014 and February 2020, we retrospectively analyzed the data of a total of 123 singleton pregnant women with SLE (mean age: 27.1±4.1 years; range, 19 to 39 years) who were referred to our rheumatology clinic. Demographic, clinical, and laboratory data of the patients were recorded. Adverse pregnancy outcomes (APOs) were assessed.

Results: Multivariate logistic regression analysis revealed that preeclampsia was associated with the increased odds of APOs (odds ratios [OR]=9.538, 95% confidence interval [CI]: 2.055-44.271, p=0.004), premature birth (OR=14.289, 95% CI: 3.596-56.777, p<0.001) and low birth weight (OR=8.275, 95% CI: 2.117-32.345, p=0.002). Anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody positivity was the predictor of APOs (OR=2.165, 95% CI: 1.034-4.532, p=0.040), premature birth (OR=2.849, 95% CI: 1.220-6.657, p=0.016) and pregnancy loss (OR=3.004, 95% CI: 1.086-8.305, p=0.034). The use of hydroxychloroquine and prednisone was associated with the decreased odds of APOs (OR=0.412, 95% CI: 0.198-0.860, p=0.018) and pregnancy loss (OR=0.304, 95% CI: 0.111-0.831, p=0.020).

Conclusion: Our study results indicate that preeclampsia, anti-dsDNA antibody positivity, and the use of hydroxychloroquine and prednisone are independent predictors of pregnancy outcomes.

Introduction

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with an incidence of 20 to 70 per 100,000 person-years worldwide.[1] In particular, SLE is associated with a strong female predominance and diagnosed more frequently in their reproductive years.[2] It is currently well-documented that pregnancy in SLE-affected women encounter an increased risk of obstetric complications such as preeclampsia, miscarriage, preterm delivery, fetal growth restriction, and low fetal birth weight.[3,4] Indeed, pregnancy outcomes in pregnant women with SLE have dramatically improved due to meaningful management, including pre-pregnancy counseling, prenatal diagnosis, progression of immunosuppressive therapy, and family planning.[5,6] Nevertheless, the diagnosis and management of pregnant women with SLE have proven to be complicated and are still challenging either for physicians or patients.

Systemic lupus erythematosus is an inflammatory multi-system disease characterized by a broad range of clinical manifestations and prognosis.[7] Although several studies have shown that SLE has adverse effects on pregnant women and their offspring, the underlying pathogenesis contributing to pregnancy complications remains being actively investigated.[8] Identification of clinical and laboratory predictors of adverse pregnancy outcomes (APOs) have significantly reduced the maternal and fetal risks in pregnant women with SLE. Previous studies have demonstrated that disease-related factors such as active disease, renal involvement, high dose use of corticosteroid and cyclophosphamide have a great predictive value for the occurrence of APOs in pregnant women with SLE.[9-11] Moreover, other factors including socioeconomic status, behavior, and genetic factors have been also implicated in the major maternal, obstetrical, and neonatal complications.[12] Of particular interest is the fact that the results of these studies are controversial and vary according to region and ethnicity.[13,14] To the best of our knowledge, there is a paucity of data on the pregnancy of Hakka women with SLE in the literature. In this study, therefore, we aimed to identify predictors of maternal and fetal outcomes in Hakka pregnant women with SLE in the southern China.

Patients and Methods

This single-center, retrospective study was conducted at the rheumatology clinic of the Meizhou People’s Hospital of the Southern China between June 2014 and February 2020. The data of a total of 123 singleton pregnant women with SLE (mean age: 27.1±4.1 years; range, 19 to 39 years) who were referred to our clinic were analyzed. All pregnant women who underwent prenatal follow-up and diagnosed with SLE and met the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) 2012 diagnostic criteria[15] were collected. Rheumatologists and fetal-maternal medicine specialists treated the patients regularly. Exclusion criteria were as follows: age <18 years, having a malignancy, having missing data, and those who were lost-to-follow-up or who did not give birth at our institution. A written informed consent was obtained from each patient. The study protocol was approved by the Meizhou People’s Hospital, Ethics Committee (No: MPH-HEC 2014-A-02). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Data collection and definitions

Using the hospital electronic database, the medical records of patients were comprehensively reviewed to collect demographic and clinical information and laboratory data. Recorded findings included maternal age at pregnancy age, gestational age at delivery, mode of delivery, disease duration of SLE, gravidity, previous pregnancy loss, blood pressure, type of current medications, lupus nephritis, thrombocytopenia, preeclampsia, diabetes, hypoalbuminemia, and Appearance, Pulse, Grimace, Activity and Respiration (APGAR) score at 1 min and 5 min. Disease activity scores were evaluated using the SLE Disease Activity Index (SLEDAI). Medication use during pregnancy was restricted to hydroxychloroquine, prednisone, and cyclosporine for the treatment of SLE. Hydroxychloroquine was prescribed to patients with a dose of 100 to 400 mg daily. Prednisone was prescribed 10 to 15 mg daily to patients with mild disease activity, 15 to 30 mg daily to patients with moderate disease activity, and over 30 mg daily to patients with high disease activity. Therapeutic doses of cyclosporine ranged from 25 to 100 mg twice daily. Laboratory parameters included serum levels of the antinuclear antibody (ANA), anti-phospholipid antibodies, anti-doublestranded deoxyribonucleic acid (anti-dsDNA) antibodies, anti-Sjögren syndrome antigen A (anti-SSA)/Ro antibodies, Sjögren syndrome antigen B (SSB)/La antibodies, complement 3, and complement 4. All laboratory tests were performed according to the manufacturer's protocols.

Preeclampsia was defined as a de novo persistent hypertension (blood pressure >140/90 mmHg) with proteinuria >300 mg/24 h collection after 20 weeks of gestation. Premature birth was defined as births less than 37 weeks of pregnancy. Low-birth-weight was defined as weight at birth of <2,500 g. Fetal growth restriction (FGR) was defined as an estimated fetal weight below the 10^th percentile for a given gestational age plus abnormal Doppler flow velocimetry waveform. Pregnancy loss included spontaneous abortions, therapeutic abortion, elective abortion, stillbirth, and neonatal death. Among these, stillbirth was defined as the occurrence of intrauterine fetal demise after at or 22 weeks of gestation. Neonatal death was defined as death within the first 28 days of birth. Adverse pregnancy outcomes were defined as the occurrence of one or more of the following: preterm delivery, low birth weight, pregnancy loss, FGR, and fetal distress.

Statistical analysis

Statistical analysis was performed using the PASW version 18.0 software (SPSS Inc., Chicago, IL, USA). Descriptive data were expressed in mean ± standard deviation (SD), median (minmax) or number and frequency. Continuous variables were compared using the Student t-test, while categorical variables were compared using the chi-square test or Fisher exact test. Univariate and multivariate logistic regression analyses were performed to identify factors yielding odds ratios (ORs) and 95% confidence intervals (CIs). A p value of <0.05 was considered statistically significant.

Results

Maternal and pregnancy outcomes in pregnant women with SLE are summarized in Table 1. Among the patients, 32/107 (29.9%) had normal vaginal delivery and 75/107 (70.1%) had cesarean-section delivery, resulting in 62/107 (57.9%) had normal birth weight and 45/107 (42.1%) had low birth weight. In addition, 17/123 (13.8%) had preeclampsia and 14/123 (11.4%) had diabetes. The full-term birth and premature birth were calculated as 74/107 (69.2%) and 33/107 (30.8%), respectively. Our study showed 7/107 (6.5%) had FGR and 12/107 (11.2%) had fetal distress. In cases of pregnancy loss (n=19), four (3.3%) had spontaneous abortion, nine (7.3%) had therapeutic abortion, three (2.4%) had stillbirth, and three (2.4%) had neonatal death.

Table 1. Maternal and pregnancy outcomes in pregnant women with SLE (n=123)

Demographic and baseline clinical characteristics of the patients with and without APOs are shown in Table 2. The frequencies of preeclampsia were 25.4% (n=15) for the patients with APOs and 3.1% (n=2) for the patients without APOs, indicating a statistically significant difference (p=0.001). The rates of anti-dsDNA antibody positivity were significantly higher in patients with APOs, compared to those without APOs (50.8% vs. 7.9%, respectively; p=0.030). The rate of hydroxychloroquine use was significantly lower in patients with APOs than that without APOs (44.1% vs. 67.2%, respectively; p=0.012).

Table 2. Clinical characteristics of patients with and without APOs (n=123)

The univariate and multivariate logistic regression analyses of predictive factors for adverse maternal and fetal outcomes are shown in Table 3. After adjusting for age, preeclampsia was associated with the increased odds of APOs (OR=9.538, 95% CI: 2.055-44.271, p=0.004), premature birth (OR=14.289, 95% CI: 3.596-56.777, p<0.001) and low birth weight (OR=8.275, 95% CI: 2.117-32.345, p=0.002). Anti-dsDNA antibody positivity was the predictor of APOs (OR=2.165, 95% CI: 1.034-4.532, p=0.040), premature birth (OR=2.849, 95% CI: 1.220-6.657, p=0.016), and pregnancy loss (OR=3.004, 95% CI: 1.086-8.305, p=0.034). In contrast, the use of hydroxychloroquine and prednisone was associated with the decreased odds of APOs (OR=0.412, 95% CI: 0.198-0.860, p=0.018) and pregnancy loss (OR=0.304, 95% CI: 0.111-0.831, p=0.020).

Table 3. Univariate and multivariate analysis results

Discussion

Maternal and pregnancy outcomes in pregnant women with SLE are summarized in Table 1. Among the patients, 32/107 (29.9%) had normal vaginal delivery and 75/107 (70.1%) had cesarean-section delivery, resulting in 62/107 (57.9%) had normal birth weight and 45/107 (42.1%) had low birth weight. In addition, 17/123 (13.8%) had preeclampsia and 14/123 (11.4%) had diabetes. The full-term birth and premature birth were calculated as 74/107 (69.2%) and 33/107 (30.8%), respectively. Our study showed 7/107 (6.5%) had FGR and 12/107 (11.2%) had fetal distress. In cases of pregnancy loss (n=19), four (3.3%) had spontaneous abortion, nine (7.3%) had therapeutic abortion, three (2.4%) had stillbirth, and three (2.4%) had neonatal death.

Demographic and baseline clinical characteristics of the patients with and without APOs are shown in Table 2. The frequencies of preeclampsia were 25.4% (n=15) for the patients with APOs and 3.1% (n=2) for the patients without APOs, indicating a statistically significant difference (p=0.001). The rates of anti-dsDNA antibody positivity were significantly higher in patients with APOs, compared to those without APOs (50.8% vs. 7.9%, respectively; p=0.030). The rate of hydroxychloroquine use was significantly lower in patients with APOs than that without APOs (44.1% vs. 67.2%, respectively; p=0.012).

The univariate and multivariate logistic regression analyses of predictive factors for adverse maternal and fetal outcomes are shown in Table 3. After adjusting for age, preeclampsia was associated with the increased odds of APOs (OR=9.538, 95% CI: 2.055-44.271, p=0.004), premature birth (OR=14.289, 95% CI: 3.596-56.777, p<0.001) and low birth weight (OR=8.275, 95% CI: 2.117-32.345, p=0.002). Anti-dsDNA antibody positivity was the predictor of APOs (OR=2.165, 95% CI: 1.034-4.532, p=0.040), premature birth (OR=2.849, 95% CI: 1.220-6.657, p=0.016), and pregnancy loss (OR=3.004, 95% CI: 1.086-8.305, p=0.034). In contrast, the use of hydroxychloroquine and prednisone was associated with the decreased odds of APOs (OR=0.412, 95% CI: 0.198-0.860, p=0.018) and pregnancy loss (OR=0.304, 95% CI: 0.111-0.831, p=0.020).

Citation: Zhang K, He C, Deng Q, Li W, Zhong Z, Hou J. Clinical study of factors associated with pregnancy outcomes in pregnant women with systemic lupus erythematosus in the southern China. Arch Rheumatol 2022;37(1):59-66.

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

This study was supported by Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population Grants [2018B030322003], and Science and Technology Program of Meizhou Grants [2018B007].

References

1. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology (Oxford) 2017;56:1945-61.
2. Tedeschi SK, Bermas B, Costenbader KH. Sexual disparities in the incidence and course of SLE and RA. Clin Immunol 2013;149:211-8.
3. Lin P, Rhew E, Ness RB, Peaceman A, Dyer A, McPherson D, et al. Adverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus. Lupus Sci Med 2014;1:e000024.
4. Ling N, Lawson E, von Scheven E. Adverse pregnancy outcomes in adolescents and young women with systemic lupus erythematosus: A national estimate. Pediatr Rheumatol Online J 2018;16:26.
5. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476-85.
6. Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: Prevention, diagnosis and management. Expert Rev Clin Immunol 2012;8:439-53.
7. Skorpen CG, Lydersen S, Gilboe IM, Skomsvoll JF, Salvesen KÅ, Palm Ø, et al. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: A population-based study. Ann Rheum Dis 2018;77:264-9.
8. Bundhun PK, Soogund MZ, Huang F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016. J Autoimmun 2017;79:17-27.
9. Wagner SJ, Craici I, Reed D, Norby S, Bailey K, Wiste HJ, et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 2009;18:342-7.
10. Ko HS, Ahn HY, Jang DG, Choi SK, Park YG, Park IY, et al. Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int J Med Sci 2011;8:577-83.
11. Zhang C, Liang MY, Xu X, Zhang XW, Chen S. Clinical features of new-onset systemic lupus erythematosus in pregnant patients. J Obstet Gynaecol Res 2018;44:234-40.
12. Kaplowitz ET, Ferguson S, Guerra M, Laskin CA, Buyon JP, Petri M, et al. Contribution of socioeconomic status to racial/ethnic disparities in adverse pregnancy outcomes among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2018;70:230-5.
13. Carter EE, Barr SG, Clarke AE. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016;12:605-20.
14. Manzano-Gamero V, Pardo-Cabello AJ, Vargas-Hitos JA, Zamora-Pasadas M, Navarrete-Navarrete N, Sabio JM, et al. Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: A multicenter cross-sectional study. Int J Rheum Dis 2018;21:2028-35.
15. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
16. Aoki S, Mochimaru A, Yamamoto Y, Kurasawa K, Takahashi T, Hirahara F. Pregnancy outcomes of women with coexisting systemic lupus erythematosus flare and preeclampsia. Mod Rheumatol 2015;25:410-4.
17. Tincani A, Nalli C, Khizroeva J, Bitsadze V, Lojacono A, Andreoli L, et al. Autoimmune diseases and pregnancy. Best Pract Res Clin Endocrinol Metab 2019;33:101322.
18. Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, et al. Pregnancy outcomes in women with rheumatic diseases: A real-world observational study in Japan. Lupus 2019;28:1407-16.
19. Moroni G, Doria A, Giglio E, Imbasciati E, Tani C, Zen M, et al. Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun 2016;74:194-200.
20. Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011;38:1012-6.
21. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7.
22. Koh JH, Ko HS, Kwok SK, Ju JH, Park SH. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus 2015;24:210-7.
23. Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016;214:273.e1-273.e8.
24. Seo MR, Chae J, Kim YM, Cha HS, Choi SJ, Oh S, et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 2019;28:722-30.
25. Hiramatsu Y, Yoshida S, Kotani T, Nakamura E, Kimura Y, Fujita D, et al. Changes in the blood level, efficacy, and safety of tacrolimus in pregnancy and the lactation period in patients with systemic lupus erythematosus. Lupus 2018;27:2245-52.
26. Saavedra MÁ, Sánchez A, Morales S, Ángeles U, Jara LJ. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol 2015;34:1211-6.
27. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: A prospective controlled study. Reprod Toxicol 2004;18:93-101.
28. de Jesus GR, Rodrigues BC, Lacerda MI, Dos Santos FC, de Jesus NR, Klumb EM, et al. Gestational outcomes in patients with neuropsychiatric systemic lupus erythematosus. Lupus 2017;26:537-42.
29. de Jesus GR, Mendoza-Pinto C, de Jesus NR, Dos Santos FC, Klumb EM, Carrasco MG, et al. Understanding and managing pregnancy in patients with lupus. Autoimmune Dis 2015;2015:943490.